Key result
Patients with cardiac syndrome X had significantly lower flow-mediated vasodilatation (9.06% vs 17.42%) than healthy controls, and serum ADMA concentration was an independent predictor of FMD impairment.
Case-Control (n=64)
No
Absolute Event Rate: 9.06% vs 17.42%
p-value: p=0.008
Serum ADMA concentration is an independent factor determining flow-mediated vasodilatation impairment in patients with cardiac syndrome X, highlighting its potential role in endothelial dysfunction.
May link ADMA to endothelial dysfunction in cardiac syndrome X; hypothesis-generating for therapies, pending prospective trials.
UNLABELLED: Mechanisms of decreased endogenous vascular reactivity in individuals with cardiac syndrome X (CSX) are not fully understood. AIM: To evaluate the following serum markers: total nitric oxide (NO), asymmetric dimethylarginine (ADMA), platelet-derived growth factor (PDGF), and to establish their relation to ultrasound indexes of endothelial function and structural remodeling in CSX patients. METHOD: The study group consisted of 43 CSX patients (mean age: 56.3 +/- 9 years), while the control group included 21 healthy subjects (mean age: 54.86 +/- 6.9 years). The high-resolution ultrasound was performed to measure: flow-mediated vasodilatation (FMD), nitroglycerine-mediated vasodilatation (NMD) and intima-media thickness (IMT) of carotid arteries. RESULTS: In CSX patients, significantly lower FMD (9.06 +/- 3.2%) and significantly higher IMT (0.667 +/- 0.14 mm) values were observed compared to healthy individuals (17.42 +/- 8.4%, 0.571 +/- 0.2 mm; P < 0.05). Mean total NO serum concentration was significantly higher in the CSX group (48.2 +/- 18.2 micromol/L) as compared to controls (32.1 +/- 1.4 micromol/L; P < 0.0001). There were no differences in serum ADMA and PDGF levels. In CSX patients, FMD values correlated with NO (r = 0.323; P = 0.039) and ADMA (r = -0.387; P = 0.012) serum levels; however, there were no significant correlations between NO and ADMA concentrations. CONCLUSION: Serum ADMA concentration is the only independent factor determining FMD impairment.
No takes yet. Share an insight, caveat, or question.
Haberka et al. (2009) conducted a case-control in Cardiac syndrome X (n=64). Cardiac syndrome X vs. Healthy subjects was evaluated on Flow-mediated vasodilatation (FMD) (p=0.008). Patients with cardiac syndrome X had significantly lower flow-mediated vasodilatation (9.06% vs 17.42%) than healthy controls, and serum ADMA concentration was an independent predictor of FMD impairment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: